Preferences and acceptability for long‐acting PrEP agents among pregnant and postpartum women with experience using daily oral PrEP in South Africa and Kenya
暂无分享,去创建一个
L. Myer | C. Orrell | G. John-Stewart | N. Wara | R. Hoffman | D. J. Davey | J. Pintye | C. Moucheraud | N. Mashele | J. Kinuthia | R. Mvududu | Mary M Marwa | Lauren Gomez
[1] L. Myer,et al. Adherence challenges with daily oral pre‐exposure prophylaxis during pregnancy and the postpartum period in South African women: a cohort study , 2022, Journal of the International AIDS Society.
[2] S. Delany-Moretlwe,et al. Prevalence and Risk Factors of PrEP Use Stigma Among Adolescent Girls and Young Women in Johannesburg, South Africa and Mwanza, Tanzania Participating in the EMPOWER Trial , 2022, AIDS and Behavior.
[3] S. Delany-Moretlwe,et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial , 2022, The Lancet.
[4] L. Myer,et al. Barriers to Oral HIV Pre-exposure Prophylaxis (PrEP) Adherence Among Pregnant and Post-partum Women from Cape Town, South Africa , 2022, AIDS and Behavior.
[5] T. Exner,et al. Women’s Perceptions of HIV- and Sexuality-Related Stigma in Relation to PrEP: Qualitative Findings from the Masibambane Study, Durban, South Africa , 2022, AIDS and Behavior.
[6] L. Myer,et al. Early pre‐exposure prophylaxis (PrEP) initiation and continuation among pregnant and postpartum women in antenatal care in Cape Town, South Africa , 2022, Journal of the International AIDS Society.
[7] A. van der Straten,et al. Sexual Attitudes, Beliefs, Practices, and HIV Risk During Pregnancy and Post-delivery: A Qualitative Study in Malawi, South Africa, Uganda, and Zimbabwe , 2021, AIDS and Behavior.
[8] J. Polli,et al. 885. Pregnancy Outcomes and Pharmacokinetics in Pregnant Women Living with HIV Exposed to Long-Acting Cabotegravir and Rilpivirine in Clinical Trials , 2021, HIV medicine.
[9] Gabrielle E. O'Malley,et al. Adolescent girls and young women’s PrEP-user journey during an implementation science study in South Africa and Kenya , 2021, PloS one.
[10] A. Puren,et al. Recent HIV infection among pregnant women in the 2017 antenatal sentinel cross–sectional survey, South Africa: Assay–based incidence measurement , 2021, PloS one.
[11] Ashley J. Mayo,et al. Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial , 2021, AIDS and Behavior.
[12] Ashley J. Mayo,et al. Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study. , 2021, The lancet. HIV.
[13] A. van der Straten,et al. Giving voice to the end-user: input on multipurpose prevention technologies from the perspectives of young women in Kenya and South Africa , 2021, Sexual and reproductive health matters.
[14] Gabrielle E. O'Malley,et al. Influences on early discontinuation and persistence of daily oral PrEP use among Kenyan adolescent girls and young women: a qualitative evaluation from a PrEP implementation program. , 2020, Journal of acquired immune deficiency syndromes.
[15] L. Myer,et al. Maternal PrEP Use in HIV-Uninfected Pregnant Women in South Africa: Role of Stigma in PrEP Initiation, Retention and Adherence , 2020, AIDS and Behavior.
[16] J. Baeten,et al. Exploring the Use of Oral Pre-exposure Prophylaxis (PrEP) Among Women from Durban, South Africa as Part of the HIV Prevention Package in a Clinical Trial , 2020, AIDS and Behavior.
[17] B. Chi,et al. Defining gaps in pre-exposure prophylaxis delivery for pregnant and post-partum women in high-burden settings using an implementation science framework. , 2020, The lancet. HIV.
[18] J. Baeten,et al. Community Perceptions About Use of Pre-exposure Prophylaxis Among Adolescent Girls and Young Women in Kenya. , 2020, The Journal of the Association of Nurses in AIDS Care : JANAC.
[19] M. Boeri,et al. Preferences for long‐acting Pre‐Exposure Prophylaxis (PrEP) for HIV prevention among South African youth: results of a discrete choice experiment , 2020, Journal of the International AIDS Society.
[20] A. van der Straten,et al. Influences on willingness to use vaginal or oral HIV PrEP during pregnancy and breastfeeding in Africa: the multisite MAMMA study , 2020, Journal of the International AIDS Society.
[21] J. Baeten,et al. PrEP rollout in Africa: status and opportunity , 2020, Nature Medicine.
[22] J. Justman,et al. Safety and tolerability of injectable Rilpivirine LA in HPTN 076: A phase 2 HIV pre-exposure prophylaxis study in women , 2020, EClinicalMedicine.
[23] S. Delany-Moretlwe,et al. The influence of HIV‐related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study , 2020, Journal of the International AIDS Society.
[24] J. Baeten,et al. Pre-exposure prophylaxis uptake and early continuation among pregnant and post-partum women within maternal and child health clinics in Kenya: results from an implementation programme. , 2019, The lancet. HIV.
[25] A. van der Straten,et al. Efficacy is Not Everything: Eliciting Women’s Preferences for a Vaginal HIV Prevention Product Using a Discrete-Choice Experiment , 2019, AIDS and Behavior.
[26] B. Chi,et al. The landscape for HIV pre-exposure prophylaxis during pregnancy and breastfeeding in Malawi and Zambia: A qualitative study , 2019, PloS one.
[27] J. Justman,et al. Acceptability of a long‐acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076) , 2019, Journal of the International AIDS Society.
[28] L. Myer,et al. HIV incidence during breastfeeding and mother-to-child transmission in Cape Town, South Africa. , 2019, AIDS.
[29] D. Szydlo,et al. Contraceptive method switching among women living in sub-Saharan Africa participating in an HIV-1 prevention trial: a prospective cohort study. , 2019, Contraception.
[30] A. van der Straten,et al. End‐user preference for and choice of four vaginally delivered HIV prevention methods among young women in South Africa and Zimbabwe: the Quatro Clinical Crossover Study , 2019, Journal of the International AIDS Society.
[31] Gabrielle E. O'Malley,et al. PrEP Implementation for Mothers in Antenatal Care (PrIMA): study protocol of a cluster randomised trial , 2019, BMJ Open.
[32] A. van der Straten,et al. “We are not the same”: African women’s view of multipurpose prevention products in the TRIO clinical study , 2019, International journal of women's health.
[33] L. Bekker,et al. Global PrEP roll-out: recommendations for programmatic success. , 2019, The lancet. HIV.
[34] A. van der Straten,et al. Young Women's Stated Preferences for Biomedical HIV Prevention: Results of a Discrete Choice Experiment in Kenya and South Africa , 2019, Journal of acquired immune deficiency syndromes.
[35] J. Baeten,et al. HIV-Uninfected Kenyan Adolescent and Young Women Share Perspectives on Using Preexposure Prophylaxis During Pregnancy. , 2018, AIDS patient care and STDs.
[36] A. van der Straten,et al. The Tablets, Ring, Injections as Options (TRIO) study: what young African women chose and used for future HIV and pregnancy prevention , 2018, Journal of the International AIDS Society.
[37] Ashley J. Mayo,et al. Acceptability and use of a dapivirine vaginal ring in a phase III trial. , 2017, AIDS.
[38] Qingfeng Li,et al. Contraceptive Practice in Sub-Saharan Africa. , 2017, Population and development review.
[39] A. van der Straten,et al. Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa , 2016, PloS one.
[40] S. A. Abdool Karim,et al. Trends in HIV Prevalence in Pregnant Women in Rural South Africa , 2015, Journal of acquired immune deficiency syndromes.
[41] G. Rutherford,et al. Mother-to-Child Transmission of HIV in Kenya: Results From a Nationally Representative Study , 2014, Journal of acquired immune deficiency syndromes.
[42] K. Grumbach,et al. Women's preferences for contraceptive counseling and decision making. , 2013, Contraception.
[43] J. R. Koch,et al. A preliminary investigation of the AUDIT and DUDIT in comparison to biomarkers for alcohol and drug use among HIV-infected clinic attendees in Cape Town, South Africa. , 2012, African journal of psychiatry.
[44] Matt Stevenson,et al. Alcohol Use Disorders Identification Test , 2010 .
[45] D. Kivlahan,et al. The AUDIT Alcohol Consumption Questions (AUDIT-C) An Effective Brief Screening Test for Problem Drinking , 2010 .
[46] P. Harris,et al. Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.
[47] I. Kleinschmidt,et al. Young people's sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey , 2005, AIDS.
[48] Christine A Varga,et al. How gender roles influence sexual and reproductive health among South African adolescents. , 2003, Studies in family planning.
[49] D. Kivlahan,et al. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. , 1998, Archives of internal medicine.
[50] H. Klein,et al. The Pre-Exposure Prophylaxis (PrEP) Stigma Scale: Preliminary findings from a pilot study. , 2019, International public health journal.
[51] S. Delany-Moretlwe,et al. Divergent Preferences for HIV Prevention: A Discrete Choice Experiment for Multipurpose HIV Prevention Products in South Africa , 2018, Medical decision making : an international journal of the Society for Medical Decision Making.